Xp11.2 translocation renal cell carcinomas in young adults

Linfeng Xu,Rong Yang,Weidong Gan,Xiancheng Chen,Xuefeng Qiu,Kai Fu,Jin Huang,Guancheng Zhu,Hongqian Guo

DOI: https://doi.org/10.1186/s12894-015-0055-0

2015-01-01

BMC Urology

Abstract:Background Little is known about the biological behavior of Xp11.2 translocation renal cell carcinomas (RCCs) as few clinical studies have been performed using a large sample size. Methods This study included 103 consecutive young adult patients (age ≤ 45 years) with RCC who underwent partial or radical nephrectomy at our institution from 2008 to 2013. Five patients without complete clinical data were excluded. Of the 98 remaining patients, 16 and 82 patients were included in the Xp11.2 translocation and non-Xp11.2 translocation groups, respectively. Clinicopathologic data were collected, including age, gender, tumor size, laterality, symptoms at diagnosis, surgical procedure, pathologic stage, tumor grade, time of recurrence and death. Results Xp11.2 translocation RCCs were associated with higher tumor grade and pathologic stage ( P < 0.05, Fisher’s exact test). During the median follow-up of 36 months (range: 3–71 months), the number of cancer-related deaths was 4 (4.9 %) and 3 (18.7 %) in the non-Xp11.2 translocation and Xp11.2 translocation groups, respectively. The Kaplan-Meier cancer specific survival curves revealed a significant difference between non-Xp11.2 translocation RCCs and Xp11.2 translocation RCCs in young adults ( P = 0.042). Conclusions Compared with non-Xp11.2 translocation RCCs, the Xp11.2 translocation RCCs seemingly showed a higher tumor grade and pathologic stage and have similar recurrence-free survival rates but poorer cancer-specific survival rates in young adults.